Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Statistical approaches for evaluating body composition markers in clinical cancer research journalArticle 2017 Bayar, M. A.; Antoun, S.; Lanoy, E.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
[Proton therapy for head and neck cancers] journalArticle 2017 Blanchard, P.; Frank, S. J.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma journalArticle 2017 Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial journalArticle 2017 Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab journalArticle 2017 Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? journalArticle 2017 Bossi, A.; Mottet, N.; Blanchard, P.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents journalArticle 2017 Azan, A.; Caspers, P. J.; Bakker Schut, T. C.; Roy, S.; Boutros, C.; Mateus, C.; Routier, E.; Besse, B.; Planchard, D.; Seck, A.; Kamsu Kom, N.; Tomasic, G.; Koljenovic, S.; Noordhoek Hegt, V.; Texier, M.; Lanoy, E.; Eggermont, A. M.; Paci, A.; Robert, C.; Puppels, G. J.; Mir, L. M.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Radiation-induced neurocognitive dysfunction in head and neck cancer patients journalArticle 2017 De Felice, F.; Blanchard, P.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) journalArticle 2017 Fresneau, Brice; Hackshaw, A.; Hawkins, D. S.; Paulussen, M.; Anderson, J. R.; Judson, I.; Litière, S.; Dirksen, U.; Lewis, I.; van den Berg, H.; Gaspar, N.; Gelderblom, H.; Whelan, J.; Boddy, A. V.; Wheatley, K.; Pignon, J. P.; De Vathaire, F.; Le Deley, M. C.; Le Teuff, G.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Hypofractionation for prostate cancer: a word of caution journalArticle 2016 Bossi, A.; Blanchard, P.
Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis journalArticle 2016 Chopra, H.; Arangalage, D.; Bouleti, C.; Zarka, S.; Fayard, F.; Chillon, S.; Laissy, J. P.; Henry-Feugeas, M. C.; Steg, P. G.; Vahanian, A.; Ou, P.
45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims? journalArticle 2016 Mazeron, R.; Petit, C.; Rivin, E.; Limkin, E.; Dumas, I.; Maroun, P.; Annede, P.; Martinetti, F.; Seisen, T.; Lefkopoulos, D.; Chargari, C.; Haie-Meder, C.
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials journalArticle 2016 Buyse, M.; Molenberghs, G.; Paoletti, X.; Oba, K.; Alonso, A.; Van der Elst, W.; Burzykowski, T.
Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma journalArticle 2016 Gunn, G. B.; Blanchard, P.; Garden, A. S.; Zhu, X. R.; Fuller, C. D.; Mohamed, A. S.; Morrison, W. H.; Phan, J.; Beadle, B. M.; Skinner, H. D.; Sturgis, E. M.; Kies, M. S.; Hutcheson, K. A.; Rosenthal, D. I.; Mohan, R.; Gillin, M. T.; Frank, S. J.
Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trial journalArticle 2016 Ouldamer, L.; Bonastre, J.; Brunet-Houdard, S.; Body, G.; Giraudeau, B.; Caille, A.
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice journalArticle 2016 Michiels, S.; Ternes, N.; Rotolo, F.
New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study journalArticle 2016 Bayar, M. A.; Le Teuff, G.; Michiels, S.; Sargent, D. J.; Le Deley, M. C.
Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis journalArticle 2016 Holliday, E. B.; Kocak-Uzel, E.; Feng, L.; Thaker, N. G.; Blanchard, P.; Rosenthal, D. I.; Gunn, G. B.; Garden, A. S.; Frank, S. J.
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials journalArticle 2016 Hollebecque, A.; Lanoy, E.; Troallen, F.; Soulat-Dufour, L.; Massard, C.; Bahleda, R.; Varga, A.; Gazzah, A.; Postel-Vinay, S.; Ribrag, V.; Deutsch, E.; Angevin, E.; Boccara, F.; Cohen, A.; Soria, J. C.; Ederhy, S.